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Introduction
Four questions were considered pivotal by the organizers of
the Controversies in Breast Cancer 2009 meeting in Edin-
burgh, September 2009 with regards to the radiation (RT)
effect in the adjuvant setting of early breast cancer: What are
the data indicating that local radiotherapy is associated with
long-term survival benefit? What must be irradiated to obtain
a long-term effect? What is the mechanism of action whereby
local RT can influence long-term outcome? Is the RT effect
applicable to different subsets? Answers to these questions
constitute the present contribution.
Data 1: why controversy?
Undoubtedly, until the 1997 publication of the British
Columbia and Danish randomized trials [1,2], RT was viewed
as a modality strictly affecting local control. Its widespread
use since the 1950s was halted in the early 1980s, when it
was felt that the newly emergent adjuvant chemotherapy [3,4]
would be sufficient, particularly when data of significant
cardiac toxicity due to RT became available at the same time
[5]. These data have shown more than a 20% increase in
cardiac mortality, with no identifiable systemic benefits in
reduction of systemic events.
Table 1 – based on past analyses of Oxford-based Early
Breast Cancer Trialists Collaborative Group (EBCTCG)
meta-analyses [6] – shows that trials which began with
patients diagnosed before 1970 had cardiac mortality rates
increased by 19 to 21% (hazard ratio (HR) = 1.19 to 1.21),
according to the follow-up duration, whereas trials with
patients diagnosed after 1993 had no increased risk (HR =
0.95 to 0.99).
What has changed in the past 25 years? Both the RT equip-
ment and the three-dimensional computed tomography
planning of RT fields today secure high-quality RT beams
restricted and targeted directly to the tumor or lymph node
bearing areas, with minimum scatter affecting the heart or
lungs. The therapeutic ratio has therefore substantially
increased, as reflected in the data. Another change, however,
was the emergence of adjuvant chemotherapy.
Mechanism of radiation: chemotherapy impact on
radiotherapy
In parallel with the substantial RT equipment improvement,
data also indicate evidence for more RT-associated impact in
the presence of rather than in the absence of adjuvant
chemotherapy. The hypothesis of improved chemo-RT inter-
action first articulated in [1] indicated that, in the absence of
adjuvant chemotherapy, whatever the RT impact, the patient
may die from systemic micrometastases unaffected by loco-
regional RT. On the other hand, if the systemic disease
component is eliminated by adjuvant chemotherapy, then the
residual disease at the loco-regional areas may be all that
remains. This disease is the target for curative RT treatment.
Chemotherapy sensitivity: micrometastases versus
macrometastases
The pivotal argument for this set of events comes from data
showing systemic microscopic disease at a biologically
younger age than the more bulky loco-regional disease – thus
subject to less resistance, and therefore more curable by
chemotherapy [7-9]. On the other hand, the more aged bulky
loco-regional disease would contain a higher absolute
number of chemotherapy-resistant mutants, and could be
eliminated through a nonspecific higher loco-regional cell kill
of radiotherapy[10,11].
Data 2: what is the actual radiation benefit?
The Oxford overview data [6] of RT-associated mortality
show a reduction of hazards (hazard ratio = 0.83 to 0.70),
indicating that the 17 to 30% of patients who are destined to
die in the absence of radiotherapy will live as a result of RT
preventing the systemic dissemination.
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The first two trials that have shown significant systemic RT
effect were the British Columbia and the Danish trials [1,2].
Their combined publication in 1997 in the New England
Journal of Medicine was hailed as a milestone leading to an
identifiable paradigm change: although a local modality, RT
does have a profound systemic benefit, and should be
uniformly introduced as part of guideline recommendations to
patients with positive nodes, particularly those with four or
more positive nodes involved. Data in both trials showed
breast cancer mortality reduction, regardless of the number of
lymph nodes involved (Tables 2 and 3).
The EBCTCG meta-analyses, originally not supporting the RT
systemic impact, showed finally in their 2005 update a
significant overall survival benefit of RT (HR = 0.83, range =
0.0002) (Tables 4 and 5) [6].
The benefit surprisingly is not restricted only to post-mastec-
tomy radiotherapy, but there is a clear mortality reduction
after breast-only irradiation following conservative surgery
(partial mastectomy), with 19% reduction of odds of death
(0.81, range = 0.0002) (Table 4, lower panel and Table 5).
When analyzing these data in more detail it is clear that the
major benefit of RT stems from more recent studies that
influenced the overall outcome of the Oxford overview.
Specifically, the EBCTCG radiation meta-analyses between
1990, 2000 and 2005 showed a gradually escalating
radiation benefit ratio: a 13% increased (overall) mortality in
the 1990 overview (HR = 1.13), a 4% mortality increase in
2000 (HR = 1.04), but a significant 17% mortality reduction
in 2005 (HR = 0.83). This compares with a 27 to 30%
mortality reduction (HR = 0.73 to 0.70) from the most recent
Danish and British Columbia trials.
Subsets: one to three versus four or more positive
nodes? Are there other radiation-predictive markers?
Despite these data, controversy continues to exist as regards
to the subsets of patients who would benefit from RT.
Because the risk of loco-regional recurrence increases with
the number of positive axillary lymph nodes, a widely adopted
approach, historically, has been to accept RT only for patients
with four or more positive axillary nodes. Although this
Table 1
Cardiac mortality in radiation trials before 1973 and after 1993
Hazard ratio 
Cardiac (95%  confidence 
deathsa interval)
Diagnosed before 1973
Follow up <5 years 230/180 1.19 (0.98 to 1.45)
Follow up >5 years 189/145 1.21 (0.97 to 1.50)
Diagnosed after 1993
Follow up < 5 years 230/180 0.95 (0.79 to 1.14)
Follow up > 5 years 189/145 0.99 (0.73 to 1.50)
aLeft-sided radiation versus right-sided radiation.
Table 2
Rates of breast cancer relapse and hazard ratios related to
dose intensity of chemotherapy
Dose intensity  No  Hazard 
of radiation  Radiation  ratio 
Subset chemotherapy (%) (%) (DFS)
Arriagada and colleagues [20]
Node-negative 0.0 59 47 0.70
Node-positive 82 67 0.65
Overgaard and colleagues [2]
N1 to N3 0.4 53 37 0.61
N4+ 76 60 0.64
Ragaz and colleagues [1]
N1 to N3 0.6 48 36 0.68
N4+ 83 62 0.55
Absolute and relative rates of breast cancer relapse (%) and hazard
ratios related to the dose intensity of chemotherapy. N1 to N3, one to
three axillary nodes involved; (N4+), four or more axillary nodes
involved. DFS, first event breast cancer recurrence (or any death).
Table 3
British Columbia Randomized Radiation trial, 2005 update
Hazard ratio 95% confidence interval
DFS
All patients 0.63 0.47 to 0.83
N1 to N3 0.64 0.42 to 0.97
N4+ 0.59 0.38 to 0.91
SysDFS
All patients 0.66 0.49 to 0.88
N1 to N3 0.68 0.45 to 1.04
N4+ 0.63 0.41 to 0.97
Overall survival 
All patients 0.73 0.55 to 0.98
N1 to N3 0.76 0.50 to 1.15
N4+ 0.63 0.41 to 0.97
Cyclophosphamide methotrexate, 5-fluoracil + radiation versus
cyclophosphamide methotrexate, 5-fluoracil alone, including all
patients and involving patients with one to three axillary nodes involved
(N1 to N3) and patients with four or more axillary nodes involved (N4+).
DFS, first event breast cancer recurrence (or any death); SysDFS, DFS
with systemic recurrence as a first event. Adapted from Ragaz and
colleagues [12].approach seems logical, it is not supported by the available
data.
In the studies of Ragaz and colleagues and of Overgaard and
colleagues, as published in the original 1997 New England
Journal of Medicine analyses [1,2], while patients with four or
more positive nodes involved had a higher percentage of
absolute relapses, the proportion of events reduced with the
loco-regional RT and the hazards reflecting mortality reduc-
tion are similar in patients with one to three positive nodes
versus four or more positive lymph nodes (Tables 2 and 3).
The 2005 Journal of the National Cancer Institute update of
the British Columbia trial (Table 3) confirmed these earlier
data [12]; a recent analysis from the Danish trials also
showed that the survival benefits were similar in both nodal
groups [13].
Classifying patients into groups with one to three positive
nodes versus four or more positive nodes emerged as an
artificial distinction originating from early trials of systemic
therapy in the 1970s, where it was considered that benefit of
any adjuvant therapy may be restricted only in those patients
with four or more positive lymph nodes, as toxicity for lower-
risk cases may be prohibitive. Later chemotherapy studies, as
seen from the recent EBCTCG meta-analyses [14], demon-
strated the benefit of adjuvant systemic therapy to be of
similar magnitude in patients with one to three involved nodes
and in those with the four or more, or even zero, involved
nodes [15]. The same trend is followed with RT, and the
recent Journal of Clinical Oncology editorial on the subject
concurs, indicating that ‘It is time that we dispense with the
artificial partitioning of patients into groups with one to three
versus four or morepositive nodes’ [15].
In light of the above, the focus is on other RT predictive
markers – clinical, pathological or molecular biological –
which may allow a more accurate identification of cohorts
who will derive more substantial RT benefit, from those who
derive less or none. This distinction will allow therapeutic
policies when fewer patients will be irradiated and when more
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Table 4
Effect of radiation on local recurrences and breast cancer mortality in node-negative and node-positive disease
Mastectomy + axillary  Mastectomy + 
clearance + radiation axillary clearance Radiation gain (%)
Radiation after mastectomy and axillary clearance
Isolated local recurrence (%)
Node-negative 3.1 7.8 4.9
Node-positive 7.8 29.2 17.1
Breast cancer mortality (%)
Node-negative 27.7 31.3 –3.6
Node-positive 54.7 60.1 5.4
Radiation after conservative surgery (lumpectomy, conservation)
Isolated local recurrence% 
Node-negative 10.0 29.2 19.2
Node-positive 13.1 46.5 33.4
Breast cancer mortality (%)
Node-negative 26.1 31.2 5.1
Node-positive 47.9 55.0 7.1
Adapted from Early Breast Cancer Trialists Collaborative Group [6].
Table 5
Breast cancer mortality reduction by radiation after conservative surgery (lumpectomy, conservation)
Hazard ratio Two-tailed P value
Radiotherapy only to conserved breast 0.84 0.004
Radiotherapy only to conserved breast and other sites (lymph nodes) 0.83 0.0002
Breast alone versus breast plus lymph nodes. Adapted from Early Breast Cancer Trialists Collaborative Group [6].benefit will be seen in those irradiated, at a much lower
overall cost. What are those subsets other than nodal status?
The first subset concerns estrogen receptor status, lympho-
vascular space invasion and young age. Cheng and
colleagues developed a clinical modelto predict loco-regional
recurrence rates and the impact of RT on survival. In addition
to axillary nodal status, negative estrogen-receptor status,
lymphovascular space invasion, and younger age at diagnosis
were also all found to be significant [16].
Another subset is the proportion of nodes involved. Truong
and colleagues showed from the British Columbia dataset
that not only the absolute number, but also the proportion of
nodes involved (that is, the percentage involvement rather
than the absolute number) does play a role [17].
Also, extensive nodal involvement/extracapsular spread should
be considered. Ragaz and colleagues showed that patients
with extensive lymph node replacement and/or extracapsular
spread have significantly higher recurrences, and display also
more benefit from radiation [18].
Finally, there is rising evidence that molecular prognostic
factors based on cDNA microarrays will provide more RT
predictive markers – as in the Genome Health ONCOTYPE
gene 21 or the Dutch Mamma Print assays for chemotherapy
[19].
Conclusion: new paradigms of radiation
therapy in breast cancer
The present review provides evidence of loco-regional RT
offering additional benefits over the adjuvant chemo-hormonal
therapy after surgery, with the following evolving paradigms
affecting therapeutic guidelines.
First, adjuvant chemotherapy for breast cancer may eradicate
more effectively the systemic micro-metastases than the loco-
regional ones, and will need RT to finish the job.
RT, although a local modality, does have a strong systemic
effect, significantly reducing the rate of systemic recurrences
and thus improving overall survival – both in the setting of
post mastectomy and after conservation.
While absolute recurrence rates vary with the nodal status,
the reduction of events after RT is constant and comparable
among patients with one to three positive nodes or patients
with four or more positive axillary nodes involved.
Clinical parameters other than nodal status (that is, one to
three positive nodes vs. four or more positive nodes involved) –
such as the percentage of nodes involved, the extent of nodal
involvement/extracapsular spread, the invasion of vascular
channels, estrogen receptor-negative status, HER-2/Neu-
positive status, or RT molecular biological predictive factors –
all constitute interactively indications for RT, with more
research into RT predictive markers essential.
Finally, RT may be required for most high-risk patients because
presently available chemotherapy, hormonal or biological
combinations cannot provide the optimum curative approach
for most patients with early breast cancer.
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